loading page

Response to Gefitinib/Crizotinib Combination in a Pulmonary Sarcomatoid Carcinoma Patient Harboring Concurrent EGFR Mutation and MET Amplification
  • +2
  • Xiaomeng Wang,
  • Jie Cao,
  • Shui Cao,
  • Weijiao Du,
  • Weihong Zhang
Xiaomeng Wang

Corresponding Author:[email protected]

Author Profile
Weijiao Du
Author Profile
Weihong Zhang
Author Profile


Pulmonary sarcomatoid carcinoma; non-small cell lung cancer; EGFR mutation; MET amplification; crizotinib/gefitinib
30 Nov 2020Submitted to Clinical Case Reports
27 Feb 2021Submission Checks Completed
27 Feb 2021Assigned to Editor
21 Mar 2021Reviewer(s) Assigned
29 Apr 2021Review(s) Completed, Editorial Evaluation Pending
02 May 2021Editorial Decision: Revise Minor
05 May 20211st Revision Received
07 May 2021Submission Checks Completed
07 May 2021Assigned to Editor
07 May 2021Review(s) Completed, Editorial Evaluation Pending
18 May 2021Editorial Decision: Accept